Fig. 1From: Knowledge-based repositioning of the anti-HCV direct antiviral agent Sofosbuvir as SARS-CoV-2 treatmentComparison of RdRp inhibitors of RNA viruses. The structure of the RNA-dependent RNA-polymerase inhibitors in clinical trial, Favipiravir (developed for the influenza virus) and Remdesivir (developed for the Ebola virus) are shown together with Sofosbuvir (developed for the HCV)Back to article page